Natixis Advisors L.P. Raises Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Natixis Advisors L.P. raised its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 31.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,092 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,354 shares during the period. Natixis Advisors L.P. owned about 0.07% of Jazz Pharmaceuticals worth $5,573,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Renaissance Technologies LLC grew its position in shares of Jazz Pharmaceuticals by 28.2% during the second quarter. Renaissance Technologies LLC now owns 2,555,801 shares of the specialty pharmaceutical company’s stock worth $364,355,000 after buying an additional 562,700 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Jazz Pharmaceuticals by 16.7% in the first quarter. JPMorgan Chase & Co. now owns 2,262,159 shares of the specialty pharmaceutical company’s stock worth $323,376,000 after acquiring an additional 324,080 shares during the last quarter. LSV Asset Management grew its holdings in Jazz Pharmaceuticals by 31.0% during the 1st quarter. LSV Asset Management now owns 1,001,650 shares of the specialty pharmaceutical company’s stock worth $143,185,000 after acquiring an additional 237,190 shares in the last quarter. Clark Capital Management Group Inc. grew its holdings in Jazz Pharmaceuticals by 620.5% during the 1st quarter. Clark Capital Management Group Inc. now owns 227,533 shares of the specialty pharmaceutical company’s stock worth $32,526,000 after acquiring an additional 195,951 shares in the last quarter. Finally, Smith Asset Management Group LP purchased a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $21,950,000. 87.83% of the stock is currently owned by institutional investors.

JAZZ has been the topic of a number of analyst reports. BidaskClub lowered shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Wednesday, July 24th. ValuEngine downgraded shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday. HC Wainwright reissued a “hold” rating and issued a $147.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 8th. Finally, Oppenheimer set a $176.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, July 8th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have issued a buy rating to the company. Jazz Pharmaceuticals has an average rating of “Hold” and an average target price of $169.86.



In related news, SVP Paul Treacy sold 4,371 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $137.40, for a total transaction of $600,575.40. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Catherine A. Sohn sold 726 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $135.65, for a total value of $98,481.90. Following the transaction, the director now directly owns 9,574 shares in the company, valued at approximately $1,298,713.10. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

Shares of NASDAQ:JAZZ traded up $4.62 during trading on Wednesday, hitting $131.78. 24,647 shares of the company were exchanged, compared to its average volume of 423,755. The stock has a market capitalization of $7.21 billion, a P/E ratio of 10.76, a PEG ratio of 1.03 and a beta of 1.10. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.71 and a quick ratio of 3.52. Jazz Pharmaceuticals PLC has a 12-month low of $113.52 and a 12-month high of $169.82. The firm’s 50 day moving average price is $133.17 and its 200-day moving average price is $134.77.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 EPS for the quarter, beating the Zacks’ consensus estimate of $3.16 by $0.49. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The firm had revenue of $534.13 million for the quarter, compared to the consensus estimate of $507.23 million. During the same period last year, the firm posted $3.49 EPS. The company’s revenue was up 6.7% on a year-over-year basis. As a group, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 13.44 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: What Are Treasury Bonds?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.